{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:19:01Z","timestamp":1793902741317,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41591-026-04557-6","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:02:22Z","timestamp":1786006942000},"page":"3268-3275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3917-7471","authenticated-orcid":false,"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3368-2062","authenticated-orcid":false,"given":"Baozhu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Tianjiao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-5738","authenticated-orcid":false,"given":"Jacky","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6825-3069","authenticated-orcid":false,"given":"Lieping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9001-8858","authenticated-orcid":false,"given":"Nan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-5457","authenticated-orcid":false,"given":"Gangxiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"4557_CR1","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017).","journal-title":"JAMA"},{"key":"4557_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 22, 1073\u20131113 (2020).","journal-title":"Neuro Oncol."},{"key":"4557_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown, C. E. et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. 30, 1001\u20131012 (2024).","journal-title":"Nat. Med."},{"key":"4557_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"4557_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42, 126\u2013135 (2019).","journal-title":"J. Immunother."},{"key":"4557_CR6","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med. 27, 1544\u20131552 (2021).","journal-title":"Nat. Med."},{"key":"4557_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4557_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval, A. I. et al. B7-H3: a costimulatory molecule for T cell activation and IFN-\u03b3 production. Nat. Immunol. 2, 269\u2013274 (2001).","journal-title":"Nat. Immunol."},{"key":"4557_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos, F. et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin. Cancer Res. 27, 1227\u20131235 (2021).","journal-title":"Clin. Cancer Res."},{"key":"4557_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11060-024-04855-4","volume":"171","author":"P Zhang","year":"2025","unstructured":"Zhang, P. et al. Expression features of targets for anti-glioma CAR-T cell immunotherapy. J. Neurooncol. 171, 179\u2013189 (2025).","journal-title":"J. Neurooncol."},{"key":"4557_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","volume":"47","author":"D Nehama","year":"2019","unstructured":"Nehama, D. et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. eBioMedicine 47, 33\u201343 (2019).","journal-title":"eBioMedicine"},{"key":"4557_CR12","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.7150\/ijbs.85813","volume":"19","author":"X Guo","year":"2023","unstructured":"Guo, X., Chang, M., Wang, Y., Xing, B. & Ma, W. B7-H3 in brain malignancies: immunology and immunotherapy. Int. J. Biol. Sci. 19, 3762\u20133780 (2023).","journal-title":"Int. J. Biol. Sci."},{"key":"4557_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","volume":"31","author":"S Seaman","year":"2017","unstructured":"Seaman, S. et al. Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell 31, 501\u2013515 (2017).","journal-title":"Cancer Cell"},{"key":"4557_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat. Med. 31, 861\u2013868 (2025).","journal-title":"Nat. Med."},{"key":"4557_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza, N. A. et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 13, 114\u2013131 (2023).","journal-title":"Cancer Discov."},{"key":"4557_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1684127","volume":"9","author":"B Huang","year":"2020","unstructured":"Huang, B. et al. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. Oncoimmunology 9, 1684127 (2020).","journal-title":"Oncoimmunology"},{"key":"4557_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106329","volume":"182","author":"SM Sagnella","year":"2022","unstructured":"Sagnella, S. M. et al. Locoregional delivery of CAR-T cells in the clinic. Pharmacol. Res. 182, 106329 (2022).","journal-title":"Pharmacol. Res."},{"key":"4557_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath, J. et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat. Med. 26, 712\u2013719 (2020).","journal-title":"Nat. Med."},{"key":"4557_CR19","first-page":"299","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan, A. C. et al. Management of glioblastoma: state of the art and future directions. CA Cancer J. Clin. 70, 299\u2013312 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"4557_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"4557_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau, L. M. et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 9, 112\u2013121 (2023).","journal-title":"JAMA Oncol."},{"key":"4557_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150\u2013161 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4557_CR23","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen, P. Y. et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J. Clin. Oncol. 41, 5187\u20135199 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4557_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4557_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"4557_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04557-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:02:57Z","timestamp":1789480977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04557-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4557"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04557-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.F., N.X., X. Chen, J.Z. and G.H. are employees of Tcelltech. In the past 12 months, L.C. has served as a consultant for NextCure, Tcelltech, DynamiCure, Zai Lab, Chia Tai Tian Qing Pharm and OncoC4; is a scientific founder of NextCure, Tcelltech, Normunity, and DynamiCure; and has received sponsored research funding from Normunity and DynamiCure. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}